The abstract is read at the publisher; the summary is JClub's.
Response-adapted postoperative therapy after neoadjuvant sintilimab plus chemotherapy yields a 59.1% major pathologic response rate in resectable stage III–IVB LA-HNSCC.
- Why it matters: Neoadjuvant chemo-immunotherapy shows promise in LA-HNSCC, but how its postoperative radiotherapy/chemoradiotherapy effects should be adapted remained undefined.
- What they did: In an open-label phase 2 trial (NCT05476965), 30 patients received neoadjuvant sintilimab plus chemotherapy, then surgery and response-adapted PORT/POCRT based on major pathologic response.
- The result: Patients with major pathologic response received low-dose PORT (0–54 Gy) and had higher 2-year OS (100% vs. 77.8%) and DFS (100% vs. 55.6%) with fewer radiotherapy-related adverse events than non-MPR patients receiving standard PORT/POCRT.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.